AAIC 2023 | Time saved in Alzheimer’s disease in Phase III trial of donanemab

Evaluating neurodegenerative diseases by ‘time saved’ as a measure of clinical meaningfulness enables a more clear and consistent interpretation of the difference between treatment and placebo. Dr Suzanne Hendrix, PhD, from Pentara Corporation, Salt Lake City, UT, discusses an analysis of data from the recent Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) with donanemab, which shows time saved in disease progression of around 6 months over 18 months of treatment, similar to the 5.1 months of time saved demonstrated in the Phase III CLARITY-AD trial (NCT03887455) of lecanemab. Recorded at the Alzheimer’s Association International Conference (AAIC)® 2023 held in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.